Medical Advocates
Cobicistat((GS-9350) |
Last
Update:
March 11, 2015
 Documents
identified with this icon are in Portable Document Format (PDF) and require the
Adobe
Acrobat Reader |
-
Cobicistat boosts the intestinal absorption of transport
substrates including HIV protease inhibitors and GS-7340 in vitro.
Lepist EI, Phan TK, Roy A,et
al
Antimicrob Agents Chemother.
2012 Jul 30.
Abstract
-
The elvitegravir Quad pill: the first once-daily
dual-target anti-HIV tablet.
Marchand C.
Expert Opin Investig Drugs.
2012 Jul;21(7):901-4.
Abstract
-
A WEEK-IN-REVIEW FEATURED REPORT
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir
disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated
emtricitabine and tenofovir disoproxil fumarate for initial treatment of
HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority
trial.
DeJesus E, Rockstroh JK, Henry K, et al
Lancet.
2012 Jun 30;379(9835):2429-38.
Abstract
-
Effect of Cobicistat on Glomerular Filtration Rate in
Subjects with Normal and Impaired Renal Function.
German P, Liu HC, Szwarcberg J, Hepner M,
J Acquir Immune Defic Syndr.
2012 Jun 22.
Abstract
-
A WEEK-IN-REVIEW FEATURED REPORT
Phase 2 study of cobicistat versus ritonavir each with once-daily
atazanavir and fixed-dose emtricitabine/tenofovir df in the initial
treatment of HIV infection.
Elion R, Cohen C, Gathe J, et al
AIDS.
2011 Sep 24;25(15):1881-6.
-
A WEEK-IN-REVIEW FEATURED REPORT
Phase 2 Study of Cobicistat versus Ritonavir each with
Atazanavir plus Fixed-Dose Emtricitabine/Tenofovir DF in the Initial
Treatment of HIV Infection.
Elion R, Cohen C,
Gathe J, et al
AIDS. 2011 Aug 1
Abstract
-
Randomized, phase 2 evaluation of two single-tablet
regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil
fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for
the initial treatment of HIV infection.
Cohen C, Elion R, Ruane P,
et al
AIDS.
2011 Mar 27;25(6):F7-12.
Abstract
-
Pharmacokinetics and bioavailability of an integrase and
novel pharmacoenhancer-containing single-tablet fixed-dose combination
regimen for the treatment of HIV.
German P, Warren D, West S,
et al
J Acquir Immune Defic Syndr. 2010
Nov 1;55(3):323-9.
Abstract
-
Pharmacokinetics and pharmacodynamics of GS-9350: a novel
pharmacokinetic enhancer without anti-HIV activity.
Mathias AA, German P, Murray BP,
et al
Clin Pharmacol Ther. 2010
Mar;87(3):322-9.
Abstract
|
| 20th CROI |
| |
-
POSTER
Acute Hepatitis C Virus Infection in Studies of
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (Stribild) and Cobicistat
for Initial HIV-1 Therapy
Erin Quirk, H Graham, H
Liu, J Szwarcberg
PDF Poster
Abstract
|
XIX International AIDS Conference
|
-
Cobicistat versus
ritonavir as pharmacoenhancers in combination with atazanavir plus tenofovir
disoproxil fumarate/emtricitabine: phase 3 randomized, double blind,
active-controlled trial, week 48 results
J. Gallant, E. Koenig, J. Andrade-Villanueva, et al
Abstract
-
Analysis of efficacy
by baseline viral load: phase 3 study comparing
elvitegravir/cobicistat/emtricitabine/tenofovir DF (quad) versus
ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF in treatment-naïve
HIV-1-positive subjects: week 48 results
E. DeJesus, J. Rockstroh, K. Henry, et al
-
Analysis of
efficacy by baseline HIV RNA: week 48 results from a phase 3 study of
elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) compared to
efavirenz/emtricitabine/tenofovir DF in treatment-naïve HIV-1-positive
subjects
P. Sax, E. De Jesus, A. Mills,, et al
-
A WEEK-IN-REVIEW FEATURED REPORT
The
clinical and economic impact of a generic first-line antiretroviral
regimen in the U.S.
R.P. Walensky , P.E. Sax , Y.M.
Nakamura , et al
|
CROI 2010
|
|
New
and Noteworthy
Elvitegravir/Tenofovir/Emtricitabine/Cobicistat
Main
New/Newsworthy